Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EPS (Weighted Average and Diluted) (2016 - 2025)

Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at $2.4 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 241.18% year-over-year to $2.4; the TTM value through Dec 2025 reached $6.13, up 2886.36%, while the annual FY2025 figure was $6.13, 2886.36% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $2.4 at Ligand Pharmaceuticals, down from $5.68 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $5.68 in Q3 2025 and bottomed at -$2.88 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.08 (2022), against an average of $0.56.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 2950.0% in 2023 before it soared 1556.41% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.19 in 2021, then plummeted by 521.05% to -$1.18 in 2022, then skyrocketed by 187.29% to $1.03 in 2023, then plummeted by 265.05% to -$1.7 in 2024, then surged by 241.18% to $2.4 in 2025.
  • Per Business Quant, the three most recent readings for LGND's EPS (Weighted Average and Diluted) are $2.4 (Q4 2025), $5.68 (Q3 2025), and $0.26 (Q2 2025).